{"transactions":[{"id":779115,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5748,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":59.86,"underlying":"Common Stock","underlying_shares":5748},"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779114,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":57.2,"underlying":"Common Stock","underlying_shares":27600},"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779113,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7441,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":51.71,"underlying":"Common Stock","underlying_shares":7441},"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779112,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":47.28,"underlying":"Common Stock","underlying_shares":8554},"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779111,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11199,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."}],"balance_after":0,"derivative":{"exercise_price":31.91,"underlying":"Common Stock","underlying_shares":11199},"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779110,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."}],"balance_after":0,"derivative":{"exercise_price":30.62,"underlying":"Common Stock","underlying_shares":27600},"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779109,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14684,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."}],"balance_after":0,"derivative":{"exercise_price":25.12,"underlying":"Common Stock","underlying_shares":14684},"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779108,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":121894,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."}],"balance_after":0,"derivative":{"exercise_price":14,"underlying":"Common Stock","underlying_shares":121894},"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779107,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a \"Cash-Out Option\") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option."}],"balance_after":0,"derivative":{"exercise_price":13.19,"underlying":"Common Stock","underlying_shares":17580},"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779106,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"(continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779105,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7961,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"(continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779104,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5744,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"(continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779103,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3062,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"(continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any \"double-trigger\" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779102,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"other","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":false,"nature":"Indirect Owner (Spouse Trust)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"On September 7, 2021, the reporting person's spouse transferred 150,000 shares of Apellis Pharmaceuticals, Inc. common stock to her trust, of which the reporting person is the trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779101,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"other","planned":false,"acquired":false,"shares":11950,"ownership":{"direct":false,"nature":"Indirect Owner (Owned by Spouse)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Owned by spouse."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779100,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"other","planned":false,"acquired":false,"shares":250000,"ownership":{"direct":false,"nature":"Indirect Owner (Bauhaus 1 LLC)"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by Bauhaus 1 LLC, which LLC is held by The Irrevocable Agreement of Trust of Alec Machiels (the \"Trust\"). The reporting person is the managing member of Bauhaus 1 LLC and the trustee of the Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":779099,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:29:04.000Z","date":"2026-05-14","kind":"other","planned":false,"acquired":false,"shares":384989,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Apellis Pharmaceuticals, Inc. (the \"Issuer\"), Biogen Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. (\"Purchaser\"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the \"Cash Amount\"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a \"CVR\"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the \"CVR Agreement\" and the Cash Amount plus one CVR, together, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation (the \"Surviving Corporation\") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-224611","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000119312526224611/ownership.xml","form_type":"4"}},{"id":951296,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:42:04.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":14684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 1, 2026. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant."}],"balance_after":14684,"derivative":{"exercise_price":25.12,"expiration_date":"2033-12-31","underlying":"Common Stock","underlying_shares":14684},"source":{"system":"sec-edgar","filing":"0001492422-26-000014","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000149242226000014/form4.xml","form_type":"4"}},{"id":951295,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-01-05T21:42:04.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":7961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This restricted stock unit was granted on January 1, 2026. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election."}],"balance_after":384989,"source":{"system":"sec-edgar","filing":"0001492422-26-000014","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000149242226000014/form4.xml","form_type":"4"}},{"id":1314644,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-03T21:23:44.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":11199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 1, 2025. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant."}],"balance_after":11199,"derivative":{"exercise_price":31.91,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":11199},"source":{"system":"sec-edgar","filing":"0001127602-25-000436","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760225000436/form4.xml","form_type":"4"}},{"id":1314643,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-01-03T21:23:44.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":6267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This restricted stock unit was granted on January 1, 2025. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election."}],"balance_after":377028,"source":{"system":"sec-edgar","filing":"0001127602-25-000436","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760225000436/form4.xml","form_type":"4"}},{"id":1696478,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-02T21:08:19.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":5748,"price":59.86,"value":344075.28,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 1, 2024. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant."}],"balance_after":5748,"derivative":{"exercise_price":59.86,"expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":5748},"source":{"system":"sec-edgar","filing":"0001127602-24-000107","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760224000107/form4.xml","form_type":"4"}},{"id":1696477,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-02T21:08:19.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":3341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This restricted stock unit was granted on January 1, 2024. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election."}],"balance_after":370761,"source":{"system":"sec-edgar","filing":"0001127602-24-000107","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760224000107/form4.xml","form_type":"4"}},{"id":1734458,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-20T21:18:14.000Z","date":"2023-11-17","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-23-027990","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223027990/form4.xml","form_type":"4"}},{"id":1734457,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-11-20T21:18:14.000Z","date":"2023-11-17","kind":"sale","planned":true,"acquired":false,"shares":1250,"price":47.74,"value":59675.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":367420,"source":{"system":"sec-edgar","filing":"0001127602-23-027990","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223027990/form4.xml","form_type":"4"}},{"id":1734456,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-11-20T21:18:14.000Z","date":"2023-11-17","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":368670,"source":{"system":"sec-edgar","filing":"0001127602-23-027990","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223027990/form4.xml","form_type":"4"}},{"id":1758105,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-18T21:43:35.000Z","date":"2023-10-17","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":1250,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-23-026081","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223026081/form4.xml","form_type":"4"}},{"id":1758104,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-18T21:43:35.000Z","date":"2023-10-17","kind":"sale","planned":true,"acquired":false,"shares":1250,"price":48.5,"value":60625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":367420,"source":{"system":"sec-edgar","filing":"0001127602-23-026081","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223026081/form4.xml","form_type":"4"}},{"id":1758103,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-18T21:43:35.000Z","date":"2023-10-17","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":368670,"source":{"system":"sec-edgar","filing":"0001127602-23-026081","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223026081/form4.xml","form_type":"4"}},{"id":1777303,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-19T21:05:52.000Z","date":"2023-09-18","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":2500,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-23-024448","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223024448/form4.xml","form_type":"4"}},{"id":1777302,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-09-19T21:05:52.000Z","date":"2023-09-18","kind":"sale","planned":true,"acquired":false,"shares":1250,"price":45,"value":56250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":367420,"source":{"system":"sec-edgar","filing":"0001127602-23-024448","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223024448/form4.xml","form_type":"4"}},{"id":1777301,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-09-19T21:05:52.000Z","date":"2023-09-18","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":368670,"source":{"system":"sec-edgar","filing":"0001127602-23-024448","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223024448/form4.xml","form_type":"4"}},{"id":1778860,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-18T20:24:24.000Z","date":"2023-09-15","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":3750,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-23-024309","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223024309/form4.xml","form_type":"4"}},{"id":1778859,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-09-18T20:24:24.000Z","date":"2023-09-15","kind":"sale","planned":true,"acquired":false,"shares":1250,"price":45.34,"value":56675.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":367420,"source":{"system":"sec-edgar","filing":"0001127602-23-024309","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223024309/form4.xml","form_type":"4"}},{"id":1778858,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-09-18T20:24:24.000Z","date":"2023-09-15","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":368670,"source":{"system":"sec-edgar","filing":"0001127602-23-024309","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223024309/form4.xml","form_type":"4"}},{"id":1824135,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-24T21:01:36.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":false,"shares":49779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":5000,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":49779},"source":{"system":"sec-edgar","filing":"0001127602-23-021193","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223021193/form4.xml","form_type":"4"}},{"id":1824134,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-07-24T21:01:36.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":true,"shares":49779,"price":2.67,"value":132909.93,"ownership":{"direct":true},"balance_after":367420,"source":{"system":"sec-edgar","filing":"0001127602-23-021193","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223021193/form4.xml","form_type":"4"}},{"id":1824791,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-21T20:13:34.000Z","date":"2023-07-20","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":54779,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001127602-23-021137","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223021137/form4.xml","form_type":"4"}},{"id":1824790,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-07-21T20:13:34.000Z","date":"2023-07-20","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":2.67,"value":133500.0,"ownership":{"direct":true},"balance_after":317641,"source":{"system":"sec-edgar","filing":"0001127602-23-021137","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223021137/form4.xml","form_type":"4"}},{"id":1827790,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-18T20:40:51.000Z","date":"2023-07-17","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":104779,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-23-020951","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223020951/form4.xml","form_type":"4"}},{"id":1827789,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-07-18T20:40:51.000Z","date":"2023-07-17","kind":"sale","planned":true,"acquired":false,"shares":1250,"price":64.79,"value":80987.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":267641,"source":{"system":"sec-edgar","filing":"0001127602-23-020951","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223020951/form4.xml","form_type":"4"}},{"id":1827788,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-07-18T20:40:51.000Z","date":"2023-07-17","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":268891,"source":{"system":"sec-edgar","filing":"0001127602-23-020951","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223020951/form4.xml","form_type":"4"}},{"id":1847791,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-21T20:34:29.000Z","date":"2023-06-20","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":106029,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-23-019158","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223019158/form4.xml","form_type":"4"}},{"id":1847790,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-21T20:34:29.000Z","date":"2023-06-20","kind":"sale","planned":true,"acquired":false,"shares":1250,"price":88.41,"value":110512.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":267641,"source":{"system":"sec-edgar","filing":"0001127602-23-019158","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223019158/form4.xml","form_type":"4"}},{"id":1847789,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-21T20:34:29.000Z","date":"2023-06-20","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":268891,"source":{"system":"sec-edgar","filing":"0001127602-23-019158","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223019158/form4.xml","form_type":"4"}},{"id":1886849,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T21:12:45.000Z","date":"2023-05-17","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":107279,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-23-016195","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223016195/form4.xml","form_type":"4"}},{"id":1886848,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-18T21:12:45.000Z","date":"2023-05-17","kind":"sale","planned":true,"acquired":false,"shares":1250,"price":88.66,"value":110825.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":267641,"source":{"system":"sec-edgar","filing":"0001127602-23-016195","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223016195/form4.xml","form_type":"4"}},{"id":1886847,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-18T21:12:45.000Z","date":"2023-05-17","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":268891,"source":{"system":"sec-edgar","filing":"0001127602-23-016195","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223016195/form4.xml","form_type":"4"}},{"id":1918073,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-18T20:30:23.000Z","date":"2023-04-17","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":108529,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-23-013129","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223013129/form4.xml","form_type":"4"}},{"id":1918072,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-04-18T20:30:23.000Z","date":"2023-04-17","kind":"sale","planned":true,"acquired":false,"shares":1250,"price":81.05,"value":101312.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":267641,"source":{"system":"sec-edgar","filing":"0001127602-23-013129","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223013129/form4.xml","form_type":"4"}},{"id":1918071,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-04-18T20:30:23.000Z","date":"2023-04-17","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":268891,"source":{"system":"sec-edgar","filing":"0001127602-23-013129","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223013129/form4.xml","form_type":"4"}},{"id":1943042,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-21T20:35:27.000Z","date":"2023-03-17","kind":"exercise","planned":false,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":109779,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-23-010957","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223010957/form4.xml","form_type":"4"}},{"id":1943041,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-03-21T20:35:27.000Z","date":"2023-03-17","kind":"sale","planned":false,"acquired":false,"shares":1250,"price":64.03,"value":80037.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":267641,"source":{"system":"sec-edgar","filing":"0001127602-23-010957","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223010957/form4.xml","form_type":"4"}},{"id":1943040,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-03-21T20:35:27.000Z","date":"2023-03-17","kind":"exercise","planned":false,"acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":268891,"source":{"system":"sec-edgar","filing":"0001127602-23-010957","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223010957/form4.xml","form_type":"4"}},{"id":2003436,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-21T21:22:07.000Z","date":"2023-02-17","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":111029,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-23-006189","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223006189/form4.xml","form_type":"4"}},{"id":2003435,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-02-21T21:22:07.000Z","date":"2023-02-17","kind":"sale","acquired":false,"shares":1250,"price":52.38,"value":65475.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":267641,"source":{"system":"sec-edgar","filing":"0001127602-23-006189","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223006189/form4.xml","form_type":"4"}},{"id":2003434,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-02-21T21:22:07.000Z","date":"2023-02-17","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":268891,"source":{"system":"sec-edgar","filing":"0001127602-23-006189","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223006189/form4.xml","form_type":"4"}},{"id":2050804,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T21:55:00.000Z","date":"2023-01-17","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":112279,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-23-001805","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223001805/form4.xml","form_type":"4"}},{"id":2050803,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-01-19T21:55:00.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":1250,"price":52.42,"value":65525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":267641,"source":{"system":"sec-edgar","filing":"0001127602-23-001805","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223001805/form4.xml","form_type":"4"}},{"id":2050802,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-01-19T21:55:00.000Z","date":"2023-01-17","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":268891,"source":{"system":"sec-edgar","filing":"0001127602-23-001805","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760223001805/form4.xml","form_type":"4"}},{"id":2067524,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T22:37:28.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":7441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 1, 2023. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant."}],"balance_after":7441,"derivative":{"exercise_price":51.71,"expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":7441},"source":{"system":"sec-edgar","filing":"0000899243-23-000675","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924323000675/doc4.xml","form_type":"4"}},{"id":2067523,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-04T22:37:28.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":3867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This restricted stock unit was granted on January 1, 2023.  The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election."}],"balance_after":267641,"source":{"system":"sec-edgar","filing":"0000899243-23-000675","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924323000675/doc4.xml","form_type":"4"}},{"id":2081775,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-19T21:37:57.000Z","date":"2022-12-15","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":113529,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-22-027856","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222027856/form4.xml","form_type":"4"}},{"id":2081774,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-12-19T21:37:57.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":1250,"price":52.35,"value":65437.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":263774,"source":{"system":"sec-edgar","filing":"0001127602-22-027856","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222027856/form4.xml","form_type":"4"}},{"id":2081773,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-12-19T21:37:57.000Z","date":"2022-12-15","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"balance_after":265024,"source":{"system":"sec-edgar","filing":"0001127602-22-027856","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222027856/form4.xml","form_type":"4"}},{"id":2112137,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-17T21:33:36.000Z","date":"2022-11-15","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 5, 2013 and is fully vested."}],"balance_after":114779,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000899243-22-036194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924322036194/doc4.xml","form_type":"4"}},{"id":2112136,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-17T21:33:36.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":1250,"price":48.01,"value":60012.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2021."}],"balance_after":263774,"source":{"system":"sec-edgar","filing":"0000899243-22-036194","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924322036194/doc4.xml","form_type":"4"}},{"id":2112135,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-17T21:33:36.000Z","date":"2022-11-15","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2021."}],"balance_after":265024,"source":{"system":"sec-edgar","filing":"0000899243-22-036194","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924322036194/doc4.xml","form_type":"4"}},{"id":2136314,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-17T21:57:36.000Z","date":"2022-10-14","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":116029,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-22-023984","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222023984/form4.xml","form_type":"4"}},{"id":2136313,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-10-17T21:57:36.000Z","date":"2022-10-14","kind":"sale","acquired":false,"shares":1250,"price":59.31,"value":74137.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":263774,"source":{"system":"sec-edgar","filing":"0001127602-22-023984","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222023984/form4.xml","form_type":"4"}},{"id":2136312,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-10-17T21:57:36.000Z","date":"2022-10-14","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":265024,"source":{"system":"sec-edgar","filing":"0001127602-22-023984","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222023984/form4.xml","form_type":"4"}},{"id":2157305,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-16T20:03:08.000Z","date":"2022-09-15","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":117279,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-22-022540","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222022540/form4.xml","form_type":"4"}},{"id":2157304,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-09-16T20:03:08.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":1250,"price":66,"value":82500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":263774,"source":{"system":"sec-edgar","filing":"0001127602-22-022540","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222022540/form4.xml","form_type":"4"}},{"id":2157303,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-09-16T20:03:08.000Z","date":"2022-09-15","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":265024,"source":{"system":"sec-edgar","filing":"0001127602-22-022540","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222022540/form4.xml","form_type":"4"}},{"id":2184156,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-16T21:00:36.000Z","date":"2022-08-15","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":118529,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-22-021109","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222021109/form4.xml","form_type":"4"}},{"id":2184155,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-08-16T21:00:36.000Z","date":"2022-08-15","kind":"sale","acquired":false,"shares":1250,"price":67.21,"value":84012.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":263774,"source":{"system":"sec-edgar","filing":"0001127602-22-021109","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222021109/form4.xml","form_type":"4"}},{"id":2184154,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-08-16T21:00:36.000Z","date":"2022-08-15","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":265024,"source":{"system":"sec-edgar","filing":"0001127602-22-021109","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222021109/form4.xml","form_type":"4"}},{"id":2206303,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-18T21:29:35.000Z","date":"2022-07-15","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":119779,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-22-019423","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222019423/form4.xml","form_type":"4"}},{"id":2206302,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-07-18T21:29:35.000Z","date":"2022-07-15","kind":"sale","acquired":false,"shares":1250,"price":46.33,"value":57912.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":263774,"source":{"system":"sec-edgar","filing":"0001127602-22-019423","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222019423/form4.xml","form_type":"4"}},{"id":2206301,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-07-18T21:29:35.000Z","date":"2022-07-15","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":265024,"source":{"system":"sec-edgar","filing":"0001127602-22-019423","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222019423/form4.xml","form_type":"4"}},{"id":2227761,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T21:02:33.000Z","date":"2022-06-15","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":121029,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-22-017795","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222017795/form4.xml","form_type":"4"}},{"id":2227760,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-17T21:02:33.000Z","date":"2022-06-15","kind":"sale","acquired":false,"shares":1250,"price":39.29,"value":49112.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":263774,"source":{"system":"sec-edgar","filing":"0001127602-22-017795","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222017795/form4.xml","form_type":"4"}},{"id":2227759,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-17T21:02:33.000Z","date":"2022-06-15","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":265024,"source":{"system":"sec-edgar","filing":"0001127602-22-017795","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222017795/form4.xml","form_type":"4"}},{"id":2268085,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-17T21:26:56.000Z","date":"2022-05-16","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":122279,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-22-014789","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222014789/form4.xml","form_type":"4"}},{"id":2268084,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-17T21:26:56.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":1250,"price":39.18,"value":48975.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":263774,"source":{"system":"sec-edgar","filing":"0001127602-22-014789","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222014789/form4.xml","form_type":"4"}},{"id":2268083,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-17T21:26:56.000Z","date":"2022-05-16","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":265024,"source":{"system":"sec-edgar","filing":"0001127602-22-014789","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222014789/form4.xml","form_type":"4"}},{"id":2295658,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-18T23:42:32.000Z","date":"2022-04-14","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":123529,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-22-012095","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222012095/form4.xml","form_type":"4"}},{"id":2295657,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-04-18T23:42:32.000Z","date":"2022-04-14","kind":"sale","acquired":false,"shares":1250,"price":50.9,"value":63625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":263774,"source":{"system":"sec-edgar","filing":"0001127602-22-012095","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222012095/form4.xml","form_type":"4"}},{"id":2295656,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-04-18T23:42:32.000Z","date":"2022-04-14","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":265024,"source":{"system":"sec-edgar","filing":"0001127602-22-012095","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222012095/form4.xml","form_type":"4"}},{"id":2327369,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-03-18T00:59:38.000Z","date":"2022-03-15","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 where effected pursuant to a written Rule 10b5-1 trading plan adopted by the reported person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 5, 2013 and is fully vested."}],"balance_after":124779,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000899243-22-011518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924322011518/doc4.xml","form_type":"4"}},{"id":2327368,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-18T00:59:38.000Z","date":"2022-03-15","kind":"sale","acquired":false,"shares":1250,"price":39.57,"value":49462.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 where effected pursuant to a written Rule 10b5-1 trading plan adopted by the reported person."}],"balance_after":259544,"source":{"system":"sec-edgar","filing":"0000899243-22-011518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924322011518/doc4.xml","form_type":"4"}},{"id":2327367,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-18T00:59:38.000Z","date":"2022-03-15","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 where effected pursuant to a written Rule 10b5-1 trading plan adopted by the reported person."}],"balance_after":260794,"source":{"system":"sec-edgar","filing":"0000899243-22-011518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924322011518/doc4.xml","form_type":"4"}},{"id":2391805,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-16T21:29:06.000Z","date":"2022-02-15","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":126029,"derivative":{"exercise_price":2.67,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001127602-22-005298","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222005298/form4.xml","form_type":"4"}},{"id":2391804,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-02-16T21:29:06.000Z","date":"2022-02-15","kind":"sale","acquired":false,"shares":1250,"price":45.43,"value":56787.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":673774,"source":{"system":"sec-edgar","filing":"0001127602-22-005298","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222005298/form4.xml","form_type":"4"}},{"id":2391803,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-02-16T21:29:06.000Z","date":"2022-02-15","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":675024,"source":{"system":"sec-edgar","filing":"0001127602-22-005298","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222005298/form4.xml","form_type":"4"}},{"id":2404295,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-10T21:49:45.000Z","date":"2021-07-22","kind":"gift","acquired":false,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, the reporting person transferred 160,000 shares of Apellis Pharmaceuticals, Inc. common stock to his spouse."}],"balance_after":259544,"source":{"system":"sec-edgar","filing":"0000899243-22-005617","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924322005617/doc5.xml","form_type":"5"}},{"id":2432245,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option(Right to Buy)","published_at":"2022-01-20T01:15:04.000Z","date":"2022-01-14","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 5, 2013 and fully vested."}],"balance_after":27279,"derivative":{"exercise_price":2.671,"expiration_date":"2023-12-04","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000899243-22-002522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924322002522/doc4.xml","form_type":"4"}},{"id":2432244,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T01:15:04.000Z","date":"2022-01-14","kind":"sale","acquired":false,"shares":1250,"price":40.56,"value":50700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":673774,"source":{"system":"sec-edgar","filing":"0000899243-22-002522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924322002522/doc4.xml","form_type":"4"}},{"id":2432243,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T01:15:04.000Z","date":"2022-01-14","kind":"exercise","acquired":true,"shares":1250,"price":2.67,"value":3337.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a scheduled exercise and sale from 10B5-1 trading plan."}],"balance_after":675024,"source":{"system":"sec-edgar","filing":"0000899243-22-002522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000089924322002522/doc4.xml","form_type":"4"}},{"id":2449106,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":47333,"kind":"person","name":"Machiels Alec","position":1,"cik":"0001496687","reported_name":"Machiels Alec","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T02:28:04.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":8554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This represents a non-qualified stock option grant made on 1/1/2022 that vests quarterly over 1 year from the date of grant, subject to continued service as a director, and expires seven years from the date of grant."}],"balance_after":8554,"derivative":{"exercise_price":47.28,"expiration_date":"2029-12-31","underlying":"Common Stock","underlying_shares":8554},"source":{"system":"sec-edgar","filing":"0001127602-22-000725","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1496687/000112760222000725/form4.xml","form_type":"4"}}],"next_cursor":"2022-01-05T02:28:04.000000Z,2449106"}